Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.34 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29790344 | 0.98 | TAAR1 (0.36) | GAAHSD17B10ALDH1A1AMY1APDIA6 | |
| SCHEMBL478439 | 0.98 | TAAR1 (0.36) | GAAHSD17B10ALDH1A1AMY1APDIA6 | |
| SCHEMBL29488092 | 0.98 | TAAR1 (0.36) | GAAHSD17B10ALDH1A1AMY1APDIA6 | |
| SCHEMBL516227 | 0.98 | TAAR1 (0.36) | GAAHSD17B10ALDH1A1AMY1APDIA6 | |
| SCHEMBL30011160 | 0.95 | PDIA6 (0.38) | GAAHSD17B10ALDH1A1AMY1APDIA6 | |
| SCHEMBL23212122 | 0.94 | PTGS2 (0.41) | GAAHSD17B10ALDH1A1AMY1APDIA6 | |
| SCHEMBL10617632 | 0.93 | ALDH1A1 (0.38) | GAAHSD17B10ALDH1A1KDM4EPOLB | |
| SCHEMBL5861868 | 0.93 | HPGD (0.34) | GAAHSD17B10ALDH1A1MEP1BKDM4E | |
| SCHEMBL18044488 | 0.93 | PTGS1 (0.37) | GAAHSD17B10ALDH1A1AMY1AMEP1B | |
| SCHEMBL4773853 | 0.93 | HPGD (0.34) | GAAHSD17B10ALDH1A1MEP1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-2004642-B1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-07-26 | — | — | EP | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20130071733-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-03-21 | — | — | US | disclosed |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184553-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
| US-20090257953-A1 | NOVEL FLUORINE-18 LABELED RHODAMINE DERIVATIVES FOR MYOCARDIAL PERFUSION IMAGING WITH POSITRON EMISSION TOMOGRAPHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
| EP-2004642-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (Canada) Inc. (CA) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007104135-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | MDS (CANADA) INC. (CA) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257953-A1 | NOVEL FLUORINE-18 LABELED RHODAMINE DERIVATIVES FOR MYOCARDIAL PERFUSION IMAGING WITH POSITRON EMISSION TOMOGRAPHY | FABP3, MPI, TNNI3 | GAA 1992/4885HSD17B10 2625/4885ALDH1A1 1739/4885 |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | GAA 49/4885HSD17B10 4783/4885ALDH1A1 2764/4885 |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | LPXN, FCGRT, F13A1 | GAA 72/4885HSD17B10 4792/4885ALDH1A1 2824/4885 |
| US-20120184553-A1 | NOVEL COMPOUNDS | LRRK2, PARK7, PINK1 | GAA 278/4885HSD17B10 3326/4885ALDH1A1 4183/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | GAA 223/4885HSD17B10 255/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.